CELZ

CELZ is not an operating business in any investable sense — it is a clinical-stage biotech financed entirely by selling stock. FY2025 revenue was $6,000 (down 45.5% YoY) from CaverStem kits, against a $6.14M operating loss and a $6.00M net loss. Management says so plainly: they have 'generated minimal revenues' and 'do not expect to generate revenues for the foreseeable future,' with all real value contingent on the CELZ-201 Type 1 Diabetes (CREATE-1) and AlloStemSpine (ADAPT) trials clearing years of clinical and regulatory risk. The P/S of 745x and net margin of -99,917% aren't valuation signals — they're a flashing sign that the income statement is irrelevant and the stock trades purely on binary trial narrative.

The balance sheet looks superficially clean — $7.21M cash, only $285K total liabilities, 0.04x liabilities/equity — but that is the wrong lens for a cash-incinerator. Operations consumed $5.86M in FY2025, so the entire cash pile is roughly one year of runway. Management is explicit that 'even with the proceeds from our securities offerings, we will need additional capital,' and that future raises 'would cause dilution... which could be substantial.' They have already lived this: shares outstanding rose 111.4% in a single year, and the $70.6M accumulated deficit was funded by $40M+ of serial offerings across 2021, 2022, 2024 and 2025. The 3.70M share count and -$2.52 EPS point to a post-reverse-split micro-float that dilutes shareholders every time it needs to breathe.